Gingival crevicular fluid prostaglandin E-2 and thiobarbituric acid reactive substance levels in smokers and non-smokers with chronic periodontitis following phase I periodontal therapy and adjunctive use of flurbiprofen

Kurtis B., Tuter G., SERDAR M. A., Pinar S., Demirel I., Toyman U.

JOURNAL OF PERIODONTOLOGY, vol.78, no.1, pp.104-111, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 78 Issue: 1
  • Publication Date: 2007
  • Doi Number: 10.1902/jop.2007.060217
  • Journal Name: JOURNAL OF PERIODONTOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.104-111
  • Keywords: chronic periodontitis, flurbiprofen/therapeutic use, gingival crevicular fluid, prostaglandin E-2, smoking, thiobarbituric acid reactive substances, NONSTEROIDAL ANTIINFLAMMATORY DRUGS, MATRIX METALLOPROTEINASE-8, DISEASE PROGRESSION, CIGARETTE-SMOKING, TNF-ALPHA, EXPRESSION, INTERLEUKIN-1-BETA, ANTIOXIDANTS, DOXYCYCLINE, INHIBITION
  • Gazi University Affiliated: Yes

Abstract

Background: It has been established that smoking is an important risk factor for the initiation and progression of chronic periodontitis (CP). This study investigates the effects of phase I periodontal therapy and adjunctive flurbiprofen administration on prostaglandin E-2 (PGE(2)) and thiobarbituric acid reactive substance (TBARS) levels in gingival crevicular fluid (GCF) samples from smoker and non-smoker patients with CP.